Business Context and Reporting Period
This Form 8-K filing by Frequency Therapeutics, Inc. (trading symbol: FREQ) reports on the Annual Meeting of Stockholders held on June 11, 2020. The registrant is an emerging growth company incorporated in Delaware. Note: The request metadata references "Korro Bio, Inc.", but the filing text explicitly identifies the registrant as Frequency Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 19,695,746 shares were present at the meeting, representing approximately 63.5% of outstanding common stock as of the April 13, 2020 record date. Two proposals were voted upon:
- Item 1 (Election of Directors): Marc A. Cohen and David L. Lucchino were elected as Class I directors to serve until the 2023 Annual Meeting. Both nominees received zero votes against.
- Item 2 (Ratification of Auditors): The appointment of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2020, was approved.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Investor Verification Checklist
- Verify the identity of the registrant (Frequency Therapeutics, Inc.) versus the metadata label (Korro Bio, Inc.).
- Confirm the tenure of the newly elected Class I directors (Marc A. Cohen and David L. Lucchino) through the 2023 Annual Meeting.
- Review the Definitive Proxy Statement filed on April 29, 2020, for detailed background on the director nominees and auditor selection.
- Check subsequent filings for financial performance data, as this 8-K contains no financial metrics.